- Home
- PPHC vs HRTX Comparison
PPHC vs HRTX Comparison
Compare PPHC & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PPHC | HRTX |
|---|---|---|
| Founded | N/A | 1983 |
| Country | United States | United States |
| Employees | 450 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.4M | 228.3M |
| IPO Year | 2026 | 2007 |
Fundamental Metrics
Financial Performance| Metric | PPHC | HRTX |
|---|---|---|
| Price | $7.99 | $0.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 106.6K | ★ 3.8M |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $154,904,000.00 |
| Revenue This Year | N/A | $15.28 |
| Revenue Next Year | N/A | $20.29 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.36 |
| 52 Week Low | $7.01 | $0.38 |
| 52 Week High | $15.15 | $2.28 |
Technical Indicators
Market Signals| Indicator | PPHC | HRTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.69 | 34.21 |
| Support Level | N/A | $0.38 |
| Resistance Level | $14.70 | $0.46 |
| Average True Range (ATR) | 0.87 | 0.03 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 18.19 | 66.88 |
Price Performance
Historical ComparisonAbout PPHC Public Policy Holding Company Inc. Common Stock
Public Policy Holding Co Inc operates as a advisory firm. The company also operates a portfolio of independent firms that offer public affairs, crisis management, lobbying, and advocacy services on behalf of the corporate, trade association, and non-profit client organisations. Its business comprises of three reporting segments - Government Relations Consulting, Corporate Communications & Public Affairs Consulting and Compliance and Insights Services.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.